Elsevier

Biological Psychiatry

Volume 27, Issue 2, 15 January 1990, Pages 245-247
Biological Psychiatry

Brief report
Twenty-four hour urinary cortisol and catecholamine excretion in combat-related posttraumatic stress disorder,☆☆

https://doi.org/10.1016/0006-3223(90)90654-KGet rights and content

First page preview

First page preview
Click to open first page preview

References (10)

  • T.R. Kosten et al.

    Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder

    Psychoneuroendocrinology

    (1987)
  • American Psychiatric Association
  • L.M. Davidson et al.

    Chronic stress and posttraumatic stress disorders

    J Cons Clin Psychol

    (1986)
  • M. Frankenhaeuser

    Psychoneuroendocrine approaches to the study of stressful person-environment transactions

  • J.W. Mason et al.

    Urinary-free cortisol levels in posttraumatic stress disorder patients

    J Nerv Ment Dis

    (1986)
There are more references available in the full text version of this article.

Cited by (273)

  • Stress, the brain, and trauma spectrum disorders

    2020, International Review of Neurobiology
    Citation Excerpt :

    Symptoms irritability, increased startle, hyperarousal and sleep disturbance, all indicate excessive sympathetic and noradrenergic function (Bremner et al., 1996b). Consistent with this, baseline concentrations of norepinephrine and its metabolites in urine and plasma in PTSD were found to be increased (De Bellis et al., 1999; De Bellis, Lefter, Trickett, & Putnam, 1994; Lemieux & Coe, 1995; Mason, Giller, & Kosten, 1988; Yehuda, Siever, & Teicher, 1998) or unchanged (Blanchard, Kolb, Prins, Gates, & McCoy, 1991; McFall, Veith, & Murburg, 1992; Mellman, Kumar, Kulick-Bell, Kumar, & Nolan, 1995; Pitman & Orr, 1990; Southwick et al., 1993) and increased in CSF (Geracioti et al., 2001). Increased sympathetic reactivity based on heart rate, blood pressure, and skin conductance (Blanchard, Kolb, Gerardi, Ryan, & Pallmeyer, 1986; Blanchard, Kolb, Pallmeyer, & Gerardi, 1982; Bremner et al., 1996b; Malloy, Fairbank, & Keane, 1983; McFall, Murburg, Ko, & Veith, 1990; Orr et al., 1998; Orr, Lasko, Shalev, & Pitman, 1995; Orr, Pitman, Lasko, & Herz, 1993; Orr & Roth, 2000), as well as increased norepinephrine and epinephrine in plasma (Blanchard et al., 1991; McFall et al., 1992), was seen in PTSD patients exposed to traumatic reminders in the form of combat slides and sounds or personalized trauma scripts, while administration of the alpha2 adrenergic receptor antagonist, yohimbine, which increases firing of noradrenergic neurons in the locus coeruleus, increased PTSD symptoms and anxiety, as well plasma concentrations of the norepinephrine metabolite, 3-methoxy-4-hydroxyphenylglycol (MHPG) (Southwick et al., 1997, 1993).

View all citing articles on Scopus

Supported by a Merit Review and Research Career Development Award (R.K.P.) from the Veterans Administration.

☆☆

This work was performed by employees of the United States Government during the course of official duties and is therefore in the public domain.

The authors thank Joseph Schildkraut, M.D. for helpful comments, Ann Repak for technical assistance, and our subjects for their participation.

View full text